• Administered scientific programs and set priorities for committing federal funds to advocate for reproductive health.• Interacted with the extramural grant recipient community to assess research needs and opportunities.• Developed research concepts, requests for applications, program announcements, and notices of special interest. - Reproductive Medicine & Infertility - Assisted Reproductive Technology - Strategies for Diagnosis & management of Infertility - Polycystic Ovary Syndrome (PCOS) - Small Business Innovation Research (SBIR) & Small Business Technology Transfer (STTR) programs for Gynecological Health and Disease and Fertility/Infertility - Reproductive Scientist Development Program (RSDP) & Clinical Reproductive Scientist Training (CREST) Program

 Independent Pharma & Biotech consulting services with emphasis on Due Diligence & Evaluation of projects on behalf of Venture Capital firms and Pharmaceutical companies; Translating preclinical programs to FIH studies; Clinical Trial Design, Project Management and Drug Target Identification, PoC studies. Spartan Innovation- Mentor in Residence

Maipl Therapeutics specialize in addressing medical conditions related to inflammation, pain, and fibrosis and is developing radically different, first-in-class medicines to treat endometriosis-related period pain and other diseases.

Early Drug Discovery • Led the discovery team to build and maintain a pipeline of drug discovery portfolio • Progressed internal programs through different stages of drug discovery • Member of the Target Selection Committee (TSC) responsible for approving drug targets Strategy & Planning • Formulated long- and short-term strategies & developed strategic focus area • Created a strong alignment within different programs in the organization • Integral member of the GDDEI Senior Leadership Team Early Development / Translational Medicine / Clinical Trials • Translated preclinical programs to early development • Member of Early Clinical Development team for Phase 1 & 2 (clinical proof of concept) studies • Working knowledge of IND/CTA, BLA submission External Innovation & Business Development • Primary point of contact for initial evaluation of scientific merit for every external asset within the therapeutic area & member of BD Diligence & Investment Committee • Integral member of the EI & BD team involved in negotiating deals • Served as a scientific expert in industry and scientific events • Established an extensive network of academic collaborations with major research centers and KOLs

As principal investigator managed all aspects of 5 research programs in Women's Health - Role of Androgens in ovarian function, fertility & women’s health – IVF/ART, PCOS & NAFLD - Anti-Mullerian Hormone (AMH) in female fertility – DOR & Onco-fertility - Obesity, Gestational Diabetes, and its effect on Offspring Health - Pelvic Organ Prolapse-Built, mentored and led a team involving graduate students, postdoctoral fellows, visiting scientist and technicians - Generated funds through federal grants and pharmaceutical collaborations

- Led research programs on steroid hormone-induced cancer (prostate & breast), uterine leiomyomas and reproductive endocrinology- Mentored and led a team of postdoctoral fellows, graduate students, clinical fellows and technicians - Generated funds through federal, foundation grants and pharmaceutical collaborations - Initiated clinical proof of concept studies based on preclinical data

• Provided Multi-facet consulting services in translating pre-clinical studies to clinical settings, developing clinical proof of concept studies and molecular understanding of clinical observations regarding androgen priming in patients with diminished ovarian reserve.

Molecular Endocrinology

Molecular Reproductive Biology